Published in Cancer Weekly, March 4th, 2003
Faslodex was approved by the U.S. Food and Drug Administration in April 2002.
Faslodex is a novel agent, an antiestrogen with no agonist activity that acts as an estrogen receptor downregulator and is the first in a new class of treatments for breast cancer. It targets, binds to, blocks, and then degrades the estrogen receptors in breast cancer cells unlike aromatase inhibitors, that reduce the...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.